long-term treatment with anti-cd20 mabs - is it feasible?
Published 1 year ago • 630 plays • Length 2:50Download video MP4
Download video MP3
Similar videos
-
1:14
how does ublituximab compare to other anti-cd20 mabs?
-
2:21
updates on natalizumab and anti-cd20 antibodies for ms
-
3:20
how monoclonal antibodies treat cancer
-
29:38
leveraging the power of anti-cd20 mabs in patient-centric multiple sclerosis care
-
6:00
anti-cd20 antibodies
-
11:49
how do monoclonal antibodies work? rituximab, infliximab, adalimumab and others
-
3:10
immunology wars: monoclonal antibodies
-
4:44
the updated guidelines for treating migraines with cgrp-targeted monoclonal antibodies
-
3:10
ultimate i & ii trial results: briumvi gets usfda approval for mrs patients
-
21:17
new anti-cd20 antibodies for cll - are they better than rituximab?
-
3:19
real-world studies show effectiveness of anti-cgrp mabs in difficult to treat patients with migraine
-
7:04
anti-cd20 antibodies used in treating chronic lymphocytic leukemia
-
2:00
fda revokes authorization for last remaining monoclonal antibody treatment
-
3:32
monoclonal antibodies and its production
-
56:24
monoclonal antibodies: a class review
-
31:18
monoclonal antibodies in chronic rhinosinusitis: what are the risks?
-
8:24
cd-20 antibodies in chronic lymphocytic leukemia
-
9:12
should i get monoclonal antibodies for long covid? faq!
-
1:13
discontinuation and reinitiation of migraine treatment with gcrp mabs
-
54:22
monoclonal antibodies for difficult to treat pathogens: malaria
-
4:28
monoclonal antibody treatment: why it's so difficult to distribute
-
5:29
kinetic study of b cell depletion with a novel mab anti-mouse cd20, clone sa271g2